Evidence & regulatory context
- Mechanism
- Composite biologic-plus-scaffold construct with no single ChEMBL entity; no specific anti-TNF clone was named in the source, and neither recombinant HGF nor the KLD2R/heparin hydrogel has a ChEMBL record. FLAGGED: the HGF intervention query returned 465 records that were almost entirely off-target (melatonin, CAR-T, sepsis biomarker studies); the only HGF-pathway hit, NCT01039207 rilotumumab, is an anti-HGF NEUTRALISING antibody, i.e. the pharmacological opposite of HGF delivery, so it was NOT recorded as translation evidence. Class-level anti-TNF trials were also excluded because the construct's activity depends on local co-delivery, not systemic TNF blockade. Recorded as zero human trials of the construct.
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionRenalC57BL/6 (per MeSH)male (per MeSH)Injection of the hydrogel (single injection)
Model: Renal ischaemia-reperfusion injury in mice
Hydrogel co-delivery of anti-TNF-alpha and HGF lowered serum creatinine, blood urea nitrogen, tubular apoptosis and inflammation and reduced later fibrosis compared with free drug or hydrogel alone.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
